🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Palvella Therapeutics, Inc. (PVLA)
NASDAQ: PVLA · Real-Time Price · USD
147.59
+1.82 (1.25%)
Nov 20, 2026, 11:45 AM EST - Market open

Palvella Therapeutics Stock Forecast

Stock Price Forecast

According to 17 analysts polled by S&P Global, Palvella Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $233.44. The average 1-year stock price forecast is 58.17% higher than the current stock price, while the lowest is $207 (+40.25%) and the highest is $267 (+80.91%).

Price Target: $233.44 (+58.17%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$207$233.44$232$267
Change+40.25%+58.17%+57.19%+80.91%

Analyst Ratings

The average analyst rating for Palvella Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingJun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Strong Buy151515151617
Buy000000
Hold000000
Sell000000
Strong Sell000000
Total151515151617

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$246
BuyReiterates$246+66.68%Nov 20, 2026
BTIG
BTIG
Buy
Maintains
$215
BuyMaintains$215+45.67%Nov 20, 2026
Oppenheimer
Oppenheimer
Buy
Reiterates
$232
BuyReiterates$232+57.19%Nov 20, 2026
Unknown Analyst
Leerink Partners
No rating
Leerink Partners
Buy
Initiates
$228
BuyInitiates$228+54.48%Nov 16, 2026
Canaccord Genuity
Canaccord Genuity
Buy
Reiterates
$232 → $243
BuyReiterates$232 → $243+64.65%Nov 9, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
22.85M
EPS This Year
-6.25
from -3.71
EPS Next Year
-7.61
from -6.25
Fiscal YearFY 2022FY 2023FY 2024FY 2025FY 2026E
Period EndingDec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
-----
Operating Income
-18.04M-11.87M-14.10M-38.60M-87.10M
Net Income
-27.55M18.69M-17.43M-41.72M-89.13M
EPS
----3.71-6.25
Free Cash Flow
----36.02M-72.87M
No. Analysts
----15
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
Highn/a
Avgn/a
Lown/a

Revenue Growth

Revenue Growth20272028
High-
Avg-
Low-

EPS Forecast

EPS202620272028
High-4.87
Avg-6.25
Low-7.07

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-